Physician profile
Jean A Melvin
NPI 1861435208
$10,248.20
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,765 · 2020: $761 · 2021: $744 · 2022: $836 · 2023: $637 · 2024: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,255.23 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $813.16 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.05 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $353.23 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $336.03 | 2019-2022 | |
| Abbvie INC. | $286.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $283.39 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $281.22 | 2019-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $199.78 | 2019-2024 | Rexulti |
| Eisai INC. | $147.91 | 2021 | |
| Alkermes, INC. | $146.37 | 2019-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $99.50 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $81.78 | 2021-2023 | Belsomra |
| Tris Pharma INC | $81.10 | 2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $58.19 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $57.14 | 2022-2023 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $55.46 | 2022-2023 | Secuado, Xelstrym |
| Adlon Therapeutics L.P. | $45.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $27.92 | 2019 | |
| Almatica Pharma LLC | $18.71 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.71 | 2019 | |
| Neuronetics, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Melvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.